These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19578355)

  • 61. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
    Wenske S; Korets R; Cronin AM; Vickers AJ; Fleisher M; Scher HI; Pettersson K; Guillonneau B; Scardino PT; Eastham JA; Lilja H
    Int J Cancer; 2009 Feb; 124(3):659-63. PubMed ID: 19003994
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
    Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
    Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
    Mazzola CR; Ghoneim T; Shariat SF
    Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [PSA 2010--the beginning of a new era in early detection of prostate cancer].
    Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H
    Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115
    [No Abstract]   [Full Text] [Related]  

  • 65. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
    Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection.
    Sorokin I; Mian BM
    Asian J Androl; 2015; 17(6):864-9. PubMed ID: 26112489
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prostate specific antigen: an updated review.
    So A; Goldenberg L; Gleave ME
    Can J Urol; 2003 Dec; 10(6):2040-50. PubMed ID: 14704108
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular diagnosis of prostate cancer.
    Canto EI; Shariat SF; Slawin KM
    Curr Urol Rep; 2004 Jun; 5(3):203-11. PubMed ID: 15161569
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Significance of the PSA-concentration for the detection of prostate cancer].
    Stachon A
    Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels.
    Charlesworth MC; Young CY; Klee GG; Saedi MS; Mikolajczyk SD; Finlay JA; Tindall DJ
    Urology; 1997 Mar; 49(3):487-93. PubMed ID: 9123724
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
    Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
    J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.
    Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
    BMC Med; 2008 Jul; 6():19. PubMed ID: 18611265
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
    McKenzie PR; Delahunt B; Kench JG; Ross B; Lam Q; deVoss K; Tran HA; Sikaris KA
    Pathology; 2013 Jun; 45(4):343-5. PubMed ID: 23619589
    [No Abstract]   [Full Text] [Related]  

  • 75. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
    Botchorishvili G; Matikainen MP; Lilja H
    Curr Opin Urol; 2009 May; 19(3):221-6. PubMed ID: 19318948
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Personalized prostate cancer screening: improving PSA tests with genomic information.
    Witte JS
    Sci Transl Med; 2010 Dec; 2(62):62ps55. PubMed ID: 21160075
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Early detection of prostate cancer: is serum PSA testing alone sufficient?].
    Börgermann C; Vom Dorp F; Breuer G; Kliner S; Rübben H
    Urologe A; 2010 Nov; 49(11):1351-5. PubMed ID: 20959954
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Circulating microRNAs and kallikreins before and after radical prostatectomy: are they really prostate cancer markers?
    Egidi MG; Cochetti G; Serva MR; Guelfi G; Zampini D; Mechelli L; Mearini E
    Biomed Res Int; 2013; 2013():241780. PubMed ID: 24288670
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL.
    Tutrone R; Donovan MJ; Torkler P; Tadigotla V; McLain T; Noerholm M; Skog J; McKiernan J
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):607-614. PubMed ID: 32382078
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity.
    Algotar AM; Thompson PA; Ranger-Moore J; Stratton MS; Hsu CH; Ahmann FR; Nagle RB; Stratton SP
    Intern Med J; 2012 Apr; 42(4):374-80. PubMed ID: 21395960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.